Renal Cell Carcinoma: Recent Advances in Genetics and Imaging

Seminars in Ultrasound, CT and MRI

Volumn 30, Issue 4, 2009, Pages 315-325

  Choudhary, Shaile ^a   Sudarshan, Sunil ^b   Choyke, Peter L ^c   Prasad, Srinivasa R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CYTOKINE; FUMARATE HYDRATASE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; PLACEBO; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ALGORITHM; ARTICLE; BIRT HOGG DUBE SYNDROME; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG BIOAVAILABILITY; FAMILIAL CANCER; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HISTOGENESIS; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MOLECULAR BIOLOGY; ONTOGENY; PAPILLARY CARCINOMA; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; CONTRAST MEDIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMAGE ENHANCEMENT; KIDNEY; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67649889980     PISSN: 08872171     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sult.2009.03.003     Document Type: Article

References (60)

1. In: Eble J.N., Sauter G., Epstein J.I., et al. (Eds). Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs (2004), IARC Press, Lyon, France
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
4. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
5. Cheville J.C., Lohse C.M., Zincke H., et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 (2003) 612-624
6. Prasad S.R., Humphrey P.A., Catena J.R., et al. Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation. RadioGraphics 26 (2006) 1795-1806 discussion:1806-1710
7. Prasad S.R., Dalrymple N.C., and Surabhi V.R. Cross-sectional imaging evaluation of renal masses. Radiol Clin North Am 46 (2008) 95-111 vi-vii
8. Beer A.J., Dobritz M., Zantl N., et al. Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol 186 (2006) 1639-1650
9. Mancini V., Battaglia M., Ditonno P., et al. Current insights in renal cell cancer pathology. Urol Oncol 26 (2008) 225-238
10. Polascik T.J., Bostwick D.G., and Cairns P. Molecular genetics and histopathologic features of adult distal nephron tumors. Urology 60 (2002) 941-946
11. Storkel S., Steart P.V., Drenckhahn D., et al. The human chromophobe cell renal carcinoma: Its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 56 (1989) 237-245
12. Lopez-Beltran A., Scarpelli M., Montironi R., et al. WHO classification of the renal tumors of the adults. Eur Urol 2006 (2004) 798-805
13. Poston C.D., Jaffe G.S., Lubensky I.A., et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: Clinical and molecular genetic implications. J Urol 153 (1995) 22-26
14. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
15. Levy A.P., Levy N.S., and Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the Von Hippel-Lindau protein. J Biol Chem 271 (1996) 25492-25497
16. Kondo K., Klco J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the Von Hippel-Lindau protein. Cancer Cells 1 (2002) 237-246
17. Carroll V.A., and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of Von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 66 (2006) 6264-6270
18. Neumann H.P., Bender B.U., Berger D.P., et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160 (1998) 1248-1254
19. Kaelin Jr. W.G. Kidney cancer: Now available in a new flavor. Cancer Cells 14 (2008) 423-424
20. Zbar B., Glenn G., Lubensky I., et al. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol 153 (1995) 907-912
21. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
22. Schmidt L., Lubensky I., Linehan W.M., et al. Hereditary papillary renal carcinoma: Pathology and pathogenesis. Contrib Nephrol 128 (1999) 11-27
23. Sudarshan S., and Linehan W.M. Genetic basis of cancer of the kidney. Semin Oncol 33 (2006) 544-551
24. Jefferson K.P., and Gillatt D.A. Hereditary urological cancer syndromes. Nat Clin Pract Urol 4 (2007) 218-226
25. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
26. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30 (2002) 406-410
27. Merino M.J., Torres-Cabala C., Pinto P., et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31 (2007) 1578-1585
28. Birt A.R., Hogg G.R., and Dubé W.J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113 (1977) 1674-1677
29. Toro J.R., Glenn G., Duray P., et al. Birt-Hogg-Dubé syndrome: A novel marker of kidney neoplasia. Arch Dermatol 135 (1999) 1195-1202
30. Tickoo S.K., Reuter V.E., Amin M.B., et al. Renal oncocytosis: A morphologic study of fourteen cases. Am J Surg Pathol 23 (1999) 1094-1101
31. Warren M.B., Torres-Cabala C.A., Turner M.L., et al. Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol 17 (2004) 998-1011
32. Adley B.P., Smith N.D., Nayar R., et al. Birt-Hogg-Dubé syndrome: Clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 130 (2006) 1865-1870
33. Nagy A., Zoubakov D., Stupar Z., et al. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int J Cancer 109 (2004) 472-475
34. Kim J.K., Kim T.K., Ahn H.J., et al. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol 178 (2002) 1499-1506
35. Jinzaki M., Tanimoto A., Mukai M., et al. Double-phase helical CT of small renal parenchymal neoplasms: Correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 24 (2000) 835-842
36. Zhang J., Lefkowitz R.A., Ishill N.M., et al. Solid renal cortical tumors: Differentiation with CT. Radiology 244 (2007) 494-504
37. Outwater E.K., Bhatia M., Siegelman E.S., et al. Lipid in renal clear cell carcinoma: Detection on opposed-phase gradient-echo MR images. Radiology 205 (1997) 103-107
38. Hatcher P.A., Anderson E.E., Paulson D.F., et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 145 (1991) 20-23 discussion, 23-24
39. Reznek R.H. CT/MRI in staging renal cell carcinoma. Cancer Imaging 4 Spec No. A (2004) S25-S32
40. Amin M.B., Tamboli P., Javidan J., et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 26 (2002) 281-291
41. Ishikawa I., and Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 22 (1993) 135-139
42. Herts B.R., Coll D.M., Novick A.C., et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 178 (2002) 367-372
43. Shinmoto H., Yuasa Y., Tanimoto A., et al. Small renal cell carcinoma: MRI with pathologic correlation. J Magn Reson Imaging 8 (1998) 690-694
44. Roy C., Sauer B., Lindner V., et al. MR imaging of papillary renal neoplasms: Potential application for characterization of small renal masses. Eur Radiol 17 (2007) 193-200
45. Lesavre A., Correas J.M., Merran S., et al. CT of papillary renal cell carcinomas with cholesterol necrosis mimicking angiomyolipomas. AJR Am J Roentgenol 181 (2003) 143-145
46. Crotty T.B., Farrow G.M., and Lieber M.M. Chromophobe cell renal carcinoma: Clinicopathological features of 50 cases. J Urol 154 (1995) 964-967
47. Kondo T., Nakazawa H., Sakai F., et al. Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: A retrospective analysis on computed tomography and magnetic resonance imaging studies. Int J Urol 11 (2004) 817-824
48. Walther M.M., Choyke P.L., Weiss G., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153 (1995) 913-916
49. Linehan W.M., Grubb R.L., Coleman J.A., et al. The genetic basis of cancer of kidney cancer: Implications for gene-specific clinical management. BJU Int 95 suppl 2 (2005) 2-7
50. Pavlovich C.P., Walther M.M., Choyke P.L., et al. Percutaneous radio frequency ablation of small renal tumors: Initial results. J Urol 167 (2002) 10-15
51. Walther M.M., and Linehan W.M. Re: Nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J Urol 156 (1996) 480-481
52. Choyke P.L., Pavlovich C.P., Daryanani K.D., et al. Intraoperative ultrasound during renal parenchymal sparing surgery for hereditary renal cancers: A 10-year experience. J Urol 165 (2001) 397-400
53. Motzer R.J. Renal cell carcinoma: A priority malignancy for development and study of novel therapies. J Clin Oncol 21 (2003) 1193-1194
54. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13 (2007) 680s-684s
55. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
56. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
57. Ratain M.J., and Eckhardt S.G. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22 (2004) 4442-4445
58. Johnson J.R., Williams G., and Pazdur R. End points and US Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
59. Perini R., Choe R., Yodh A.G., et al. Non-invasive assessment of tumor neovasculature: Techniques and clinical applications. Cancer Metastasis Rev 27 (2008) 615-630
60. Delahunt B., Eble J.N., McCredie M.R., et al. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32 (2001) 590-595